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Background: More than 1.2 million new cases of colorectal cancer are reported each year worldwide. Despite
actual screening programs, about 50% of the patients are diagnosed at advanced tumor stages presenting poor
prognosis. Innovative screening tools could aid the detection at early stages and allow curative treatment
interventions.
Methods: A nine target multiplex serum protein biochip was generated and evaluated using a training- and
validation-set of 317 highly standardized, liquid nitrogen preserved serum samples comprising controls, adenomas,
and colon cancers.
Results: Serum levels of CEA, IL-8, VEGF, S100A11, MCSF, C3adesArg, CD26, and CRP showed significant differences
between cases and controls. The largest areas under the receiver operating characteristics curve were observed for
CEA, IL-8, and CRP. At threshold levels yielding 90% specificity, sensitivities for CEA, IL-8 and CRP were 26%, 22%,
and 17%, respectively. The most promising marker combinations were CEA + IL-8 reaching 37% sensitivity at 83%
specificity and CEA +CRP with 35% sensitivity at 81% specificity. In an independent validation set CEA+ IL-8
reached 47% sensitivity at 86% specificity while CEA +CRP obtained 39% sensitivity at 86% specificity. Early
carcinomas were detected with 33% sensitivity for CEA + IL-8 and 28% for CEA+ CRP.
Conclusions: Apart from CEA, IL-8, and CRP, the screening value of additional blood markers and the potential
advantage of combining serum biochip testing with fecal occult blood testing needs to be studied. Multiplex
biochip array technology utilizing serum samples offers an innovative approach to colorectal cancer screening.
Keywords: Multiplex protein array biochip, Colon cancer screening, Serum diagnostics, High-throughput seromics,
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Colon cancer ranks among the most frequent malignan-
cies and is the fourth leading cause of cancer-related
death worldwide [1,2]. Detection of colon cancer at
early stages is critical for curative treatment interven-
tions: although the 5-year disease-free survival for
International Union Against Cancer (UICC) stage I
tumors exceeds 90%, this rate is reduced to 63% in
UICC III and < 5% in UICC IV carcinomas [3]. Yet,* Correspondence: Jens.habermann@uni-luebeck.de
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reproduction in any medium, provided the ordespite the implementation of current screening pro-
grams about 50% of these malignancies are detected at
advanced tumor stages. Therefore, tools and method-
ologies that allow early colon cancer detection directly
impact on survival times. In present clinical practice,
screening for cancer and premalignant polyps of the
colon is based on clinical examination, the detection of
fecal occult blood, and on sigmoidoscopy or colonos-
copy [4,5]. The successful implementation of these
screening procedures has contributed to a reduction of
disease-associated mortality of colon carcinomas [6].
The persistent delay in diagnosis and the associated
high mortality rate are attributable to a low complianceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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other tests [7]. An optimal, alternative screening test
would be relatively non-invasive and achieve high pa-
tient compliance, fulfil excellent analytical performance
regarding sensitivity and specificity and still be robust
and cost-effective. Such a test can be envisioned if
changes in the composition of serum proteins could in-
dicate specific diseases and/or disease stages. Compre-
hensive serum proteome profiling for tumor-specific
markers has therefore become a field of intensive re-
search. For colon cancer screening the application of
serological testing has not been established so far, even
though very promising candidate markers have been
reported. Based on a thorough literature review, the
most promising markers were identified. By using pre-
operative serum levels for CRC diagnosis with sensitiv-
ity and specificity of 90% was reported for protein 26
(CD26) [8]. Other diagnostic approaches based on the
detection of carcinoembryonic antigen (CEA), vascular
endothelial growth factor (VEGF) [9], macrophage
colony-stimulating factor (M-CSF) [10], Nicotinamide
N-methyltransferase (NNMT) [11], or C-reactive pro-
tein (CRP) concentrations [12] reached either a high
sensitivity or specificity. Furthermore, within our con-
sortium, Interleukin 8 (IL-8) [13], Calgizzarin
(S100A11) [14] and complement component 3a (C3ade-
sArg) [15] serum levels were determined as potentially
promising biomarkers for CRC [14]. However, most of
the markers are yet to be validated in well defined,
large screening studies. Hereby, the measurement of a
disease specific panel of markers could outperform the
measurement of individual markers regarding sensitivity
and specificity. In addition, this approach could provide
a more comprehensive reflection of molecular networks
and pathophysiological conditions of diseases.
Biochip array technology allows multiplex determin-
ation of multiple biomarkers from a single sample
[16,17]. This is also relevant when volumes of clinical
samples are limited. Implementations of this technology
in clinical settings have been reported for different bio-
chip arrays including cytokines [13], cerebral and cardiacTable 1 Clinical data of the study group
Summary of clinical data of the study group consisting of colon can
patients
Parameter Value Colon cancer (CC) patients Healthy c
(n = 164)
Sex Female 68 (41.5%)
Male 96 (58.5%)
Age Range 40.5 – 99.1
(years) Mean 69.59
*All healthy patients received a full colonoscopy.arrays [18,19], adhesion molecules [20], and also detec-
tion of drug abuse [21].
The aim of this study was to apply biochip array tech-
nology to colon cancer screening. For this purpose, a
biochip array was designed and developed for the multi-
plex determination of nine serum markers allowing for
low inter-analysis variability, decreased workload and
faster processing time as well as lower costs due to high-
throughput automation. The performance of the two
biochip arrays for colon cancer screening was then eval-
uated in a training and a validation set consisting of 317




This study comprised 317 serum samples that were ran-
domly selected from 3,700 serum samples collected at
the University Clinic Schleswig-Holstein, Campus
Lübeck, Germany, between 2007 and 2011. This serum
collection belongs to the biomaterial bank ColonBiomics
being an integral part of the Surgical Center for Transla-
tional Oncology – Lübeck (SCTO-L), University of
Lübeck, and the DKH e.V. funded network North
German Tumorbank of Colorectal Cancer (ColoNet,
#108446). Serum samples were collected adhering to
the guidelines of the local ethical review board (Medical
University of Lübeck, #07-124) and according to strict
standard operation procedures. Serum samples of healthy
control patients as well as cancer patients were both
taken after bowl-preparation and prior to colonoscopy
or oncologic resection. The 317 samples comprised
164 patients with histological confirmed colon cancer
(96 men and 68 women), 34 patients with colon ad-
enomas (18 men and 16 women), and 119 healthy
controls (52 men and 67 women) (Table 1). Out of
this cohort we defined a training set of 52 healthy
controls and 81 patients with colon malignancy and
an independently collected, non-overlapping validation
set of 50 controls and 83 colon carcinoma samples.
For control patients, blood samples were obtainedcer patients, pre-malignant adenoma patients and healthy control
ontrol (H) patients Adenoma (A) patients P-value
(n = 119)* (n = 34)
67 (56.3%) 16 (47.1%) 0.738
52 (43.7%) 18 (52.9%)
19.5 – 90.8 28.1 – 86.1 0.144 (A vs H)
62.41 63.65 0.004 (CC vs H)
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inflammatory, benign, premalignant or malignant lesions
were present in this cohort. For cancer patients, blood
samples were obtained before neoadjuvant chemo- or
radiotherapy and/or surgery. Detailed clinical data of the
patient cohort are summarized in Tables 1, 2, 3.
An additional cohort of 400 serum samples was used
for a pilot study in order to optimize the prototypes of
the biochips. This cohort is part of a colon cancer
screening cohort established at the German Cancer
Research Center (DKFZ) and is described in detail in
Additional file 1: Table S1.
Sampling
All venous blood samples were obtained using serum
gel-monovettes (#01.1602, Sarstedt AG & Co, Nümbrecht,
Germany) and centrifuged at 1,550× g for 10 min at 4°C
to separate the serum. Aliquots of serum samples were
stored at −196°C within 30 min after venous puncture.
Samples were thawed on ice before multiplex assessment
on the newly designed biochips.
Development of the CRCS Multiplex Biochips
Both chips were manufactured according to standards
described [16,17]. Target analytes for the CRCS I and II
arrays were based on an extensive review of the litera-
ture [22] and own experimental data [14,15,13]. Design
input requirements were determined following literature
specifications. The product was manufactured and vali-
dated on 100 serum samples according to RandoxTable 2 Clinical data of the study group
Summary of clinical data of colon cancer patients
Parameter Value Colon cancer patients %




T status 1 10 6.3
(tumor size) 2 26 16.5
3 102 64.6
4 20 12.7
N status 0 45 52.3
(nodal status) 1 22 25.6
2 19 22.1
M status 0 40 45.5
(distant metastasis) 1 34 38.6
2 14 15.9
Tumor G1 61 74.4
grading G2 13 15.9
G3 18 9.7Laboratories’ manufacturing guidelines and procedures.
The validation followed a series of approved standard
operating procedures. The sensitivity, accuracy and pre-
cision of each assay were determined. Sensitivity was
evaluated to determine the lowest concentration that
could be accurately detected for an assay. Precision
was assessed both within runs (intra) and between
runs (inter). Three samples of known concentrations
which span the assay range were assessed 20 times as
a measure of the intra-assay precision. The precision is
expressed as the co-efficient of variation (%) over the
20 replicates. Inter-assay precision implies the assess-
ment of these 3 samples in duplicate over 10 separate
runs. Again the precision was assessed as the co-
efficient of variation (%) over 20 replicates. Deviation
of ≤ 15% is acceptable for both intra- and inter-assay
precision. Current performance data for both CRCS I
and CRCS II are shown in Additional file 2: Table S2.
Optimization of the CRCS Multiplex Biochips
Once the biochip prototypes were manufactured, a pilot
study of 400 serum samples (100 controls, 100 early ad-
enomas, 100 advanced adenomas, 100 colorectal carcin-
omas, Additional file 1: Table S1) was conducted with
the developed biochip arrays. Based on the results of the
pilot study, incubation times were changed from 2 x
30 min to 2 x 60 min in order to improve sensitivity. In
addition, changes to some assay ranges were implemen-
ted for the subsequent manufacturing process: C3ade-
sArg was changed from 0 – 1.8 μg/mL to 0 – 600 ng/mL,
M-CSF from 0 – 1 ng/mL to 0 – 500 pg/mL, NNMT
from 0 – 50 ng/mL to 0 – 70 ng/mL and S100A11 chan-
ged from 0 – 50 ng/mL to 0 – 200 ng/mL.
Determination of biomarker serum levels
Two biochip platforms were designed for the simultan-
eous quantitative detection of the nine-biomarkers bio-
chip array in combination with the Evidence Investigator
analyser (Randox Laboratories Ltd., Crumlin, UK). Due
to different assay- and detection ranges of some biomar-
kers, the nine chosen serum markers had to be subdi-
vided onto two biochip platforms: One biochip (CRCSI)
comprised C3desArg, CD26 and CRP, and the other bio-
chip (CRCSII) incorporated IL-8, CEA, VEGF, M-CSF,
S100A11 and NNMT. Both biochips were manufac-
tured according to standards described [16], and assay
ranges and sensitivities for each analyte were measured
(Additional file 2: Table S2).
Both biochip arrays are based on simultaneous chemi-
luminescent sandwich immunoassays. Capture anti-
bodies, specific for each biomarker are bound to the
biochip surface defining arrays of test sites. The biochip
functions as the solid phase and reaction vessel for the
immunoreactions. The assays were applied to the
Table 3 Clinical data of the study group
Summary of clinical data of colon adenoma patients








1 f 71.0 low Tubular 0.3 Non-A
2 f 28.1 low Tubular 0.7 - 1.0 A
3 m 53.0 low Tubular 1.0 A
4 m 72.0 low Tubular 1.2 A
5 m 71.8 low Tubular 1.0 - 1.5 A
6 m 58.0 low Tubular 0.3 - 0.4 Non-A
7 m 67.1 N/A Tubular 0.6 Non-A
8 f 45.9 low Tubular 0.7 Non-A
9 f 81.5 low Tubular 0.1 - 0.3 Non-A
10 m 54.0 high Tubulovillous 0.85 A
11 m 73.8 high Tubulovillous N/A A
12 f 79.8 high Tubulovillous 0.8 A
13 f 49.4 high Tubulovillous 4.5 A
14 m 54.7 high Tubulovillous 2.5 A
15 m 79.6 low Tubulovillous N/A A
16 m 63.3 low Tubulovillous 2.0 A
17 f 75.1 low Tubulovillous N/A A
18 f 52.6 low Tubulovillous N/A A
19 f 64.1 low Tubulovillous 1.0 A
20 f 73.5 low Tubular N/A Non-A
21 m 83.1 low Tubular 2.5 A
22 m 56.4 low Tubular N/A Non-A
23 m 65.8 low Tubular 0.1 - 0.2 Non-A
24 m 69.5 low Tubular N/A Non-A
25 f 32.3 low Tubular N/A Non-A
26 f 62.4 low Tubular 0.1 - 0.2 Non-A
27 f 64.5 low Tubular N/A Non-A
28 m 68.3 low Tubulovillous 2.4 A
29 f 45.1 low Tubulovillous 6.0 A
30 f 67.8 low Tubulovillous 3.0 A
31 f 86.1 low Tubulovillous 1.0 A
32 m 63.2 low Tubulovillous N/A A
33 m 63.1 low Tubulovillous N/A A
34 m 68.1 low Tubulovillous N/A A
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ling of up to 54 samples (6 x 9 wells) in biochip carriers
(Additional file 3: Figure S1). Three controls and nine
point calibration curve were run in parallel with 42 pa-
tient samples. The inclusion of controls and calibration
samples avoids the need for technical replicates for pa-
tient samples. A total of 100 μL of 1:200 diluted serum
for CRCSI and 90 μL undiluted serum samples forCRCSII were applied. Upon completion of the immunor-
eactions, the chemiluminescent signal in each test site
was detected with a super cooled charged coupled device
(CCD) incorporated with the system data automatically
processed. The detailed protocol for biochip incubation
and processing can be found as Additional file 4.
The analyser routinely assesses the quality of assay per-
formance and generates calibration curves as described
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present in the sample was calculated automatically using
generated calibration curves (Evidence Investigator Soft-
ware version 1.4).
Statistical analysis
Using SPSS Statistics version 19 (IBM Corporation, Somer,
NY) and SAS version 9.1 (SAS Institute Inc., Cary, North
Carolina, USA), the serum levels of the individual markersTable 4 Serum level of nine serum biomarkers in colon cance
control patients
Colon cancer patients (
CEA { (ng/mL) median 1.26
inter-quartile range 0.54 – 4.01
range 0.08 - 444.32
p-value
IL-8 { (pg/mL) median 27.46
inter-quartile range 20.20 – 42.36
range 0.00 - 572.58
p-value
VEGF { (pg/mL) median 77.99
inter-quartile range 46.78 – 120.94
range 5.02 - 350.38
p-value
M-CSF { (pg/mL) median 8.27
inter-quartile range 6.70 – 12.76
range 2.26 - 58.23
p-value
S100A11 { (ng/mL) median 12.14
inter-quartile range 9. 39 – 15.46
range 4.37 - 177.68
p-value
NNMT (ng/mL) median 1.48
inter-quartile range 0.72 – 4.23
range 0.25 - 70.00*
p-value
C3a desArg { (ng/mL) median 708
inter-quartile range 514 – 906
range 140 - 6114
p-value
CD26 { (ng/mL) median 442
inter-quartile range 378 – 582
range 184 - 1352
p-value
CRP { (ng/mL) median 4018
inter-quartile range 1718 – 9238
range 778 - 59800*
p-value
*Detection Limit, { Comparison of medium serum levels between colon cancer patiin colon cancer cases, colon adenoma cases and healthy
controls were described with respect to median levels,
interquartile ranges and overall ranges. Nonparametric
tests to compare median serum levels between different
patient groups were applied. The correlation between age
and sex and the serum levels of the markers as well as cor-
relations between the single markers was assessed using
Spearman’s correlation coefficient. Furthermore, receiver-
operating characteristics (ROC) curves were constructedr patients in comparison to adenoma cases and healthy
n= 164) Control patients (n= 119) Adenoma patients (n = 34)
0.51 0.82
0.36 -1.09 0.41 – 1.34
0.14 - 6.05 0.12 - 3.62
< 0.0001
20.47 19.97
16.78 – 26.21 16.20 – 26.52
0.00 - 221.15 0.00 - 158.39
< 0.0001
59.94 67.86
34.99 – 98.70 42.95 – 91.41
7.54 - 427.56 10.68 - 178.72
0.02
7.18 6.65
5.31 – 10.26 5.47 – 8.58
2.99 - 72.86 3.50 - 30.55
0.02
10.89 11.93
7.97 – 14.18 9.61 – 16.05
3.99 - 105.25 6.69 - 56.93
0.04
1.46 1.63
0.67 – 4.60 0.64 – 7.82
0.27 - 70.00* 0.28 - 70.00*
> 0.05
808 660
538 – 1134 344 – 1216
150 - 3316 200 - 3282
0.04
550 614
428 – 698 494 – 750
0.00 - 1034 82 – 3980*
0.0002
2086 2020
1188 – 5260 1208 – 4768
726 - 59800* 902 - 59800*
0.006
ents and control patients p < 0.05.
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fidence intervals (CI) for each single marker was calcu-
lated in relation to the discrimination between colon
cancer cases and controls. We also calculated the AUC for
the combination of all markers using logistic regression
analysis and compared this AUC to the AUC of the single
markers.
While logistic regression modelling focuses on the
overall AUC, we focused - in a next step – on the part
of the AUC that is most relevant for the screening set-
ting. Considering sensitivities at levels of specificity that
are typically required in the screening setting (≥ 90%),
we selected markers showing the best discriminative
power. The training set was then used to determine a
threshold level (yielding a specificity of 90%) for each of
these selected markers. The sensitivity of the marker
was then calculated at this threshold level followed by
an assessment of which marker combination could have
a beneficial affect regarding test performance. Concern-
ing the combination, individuals with at least one mar-
ker above the individual marker threshold were
classified as positive. Marker combinations were consid-
ered as beneficial if they increased sensitivity compared
to the single markers without substantially lowering the
specificity. This approach reaches for a high specificity
in order to keep the number of false-positive tests
limited.
Finally, this algorithm regarding threshold levels and
promising marker combinations that were developed in
the training set was applied to an independent validation
set including early stage carcinomas and adenomas.
Results
Here we report a comprehensive evaluation of serum
proteins in an effort to validate screening biomarkers
for colon tumors. Two multiplex biochips (CRCSI and
CRCSII) were manufactured consisting of altogether
nine serum markers and evaluated their performance
for detecting colon cancer in a minimally-invasive,
patient-friendly and reliable fashion. Biochips and tar-
gets were simultaneously evaluated in a highly standar-
dized serum collection of cancer and control samples
stored at −196°C within 30 min after phlebotomy fol-
lowing strict standard operation procedures.
Evaluation of single markers
The distribution of serum levels of all nine markers is
described in Table 4. Serum levels of CEA, IL-8, VEGF,
S100A11, C3adesArg, CD26, MCSF and CRP showed
significant differences between colon cancer cases and
controls (P < 0.05). The ROCs of the single markers
are shown in Figure 1 and the AUCs are listed in
Table 5. The three largest AUCs were observed for
CEA (0.69), IL-8 (0.68), and CRP (0.64). CEA, IL-8and CRP were also the markers whose sensitivities
were significantly different from the false-positive rate
at levels of specificity that are typically required in a
screening setting (≥ 90%).
Evaluation of marker combinations
In a first step, we assessed whether the combination of
all markers indicates an advantage in terms of increasing
the overall AUC compared to AUC of the single mar-
kers. The AUC of all markers combined as determined
by logistic regression was 0.75, which was not statisti-
cally significantly different from the largest AUC among
the single markers (i.e., the AUC of CEA). While logistic
regression modelling focuses on the overall AUC, we fo-
cused - in a next step – on the part of the AUC that is
most relevant for the screening setting. We assessed
whether there was a combination of markers that yields
an increased sensitivity when focusing on levels of speci-
ficity that are typically required in a screening setting
(≥ 90%). For that purpose, we selected CEA, IL-8 and
CRP whose sensitivities were significantly different from
the false-positive rate at these levels of specificities and
developed a test algorithm for their combination as
described below.
Development of test algorithm in the training set
Sera from 52 healthy controls and 81 patients with colon
cancer were used to develop a test algorithm. We deter-
mined threshold levels yielding a specificity of 90% for
CEA, IL-8, and CRP. For CEA the threshold was at
3.2 ng/mL, for IL-8 at 39.5 pg/mL, and for CRP at
14,600 ng/mL. Based on these threshold levels (yielding
a specificity of 90%), CEA showed a sensitivity of 26%
(95%CI: 17-37%), IL-8 of 22% (95%CI: 14-33%), and CRP
of 17% (95%CI: 10-27%; Figure 1).
We then assessed which combination of these markers
could increase the assay sensitivity without substantially
lowering its specificity. The following two combinations
showed the best results: CEA+ IL-8 reached a sensitivity
of 37% (95%CI: 27-48%) at a specificity of 83% (95%CI:
70-92%) and CEA+CRP obtained a sensitivity of 35%
(95%CI: 24-46%) at a specificity of 81% (95%CI: 67-90%).
The combination of IL-8 +CRP yielded both a lower
sensitivity and a lower specificity compared to CEA+ IL-
8 and the combination of all three markers decreased
the specificity to 73%, but increased the sensitivity by
only 4% compared to CEA+ IL-8.
Evaluation of the test algorithm in an independent
validation set
To exclude fortuitous separation of the colon carcinoma
cases from healthy controls in the training set, the test
algorithms described above were then applied to the val-
idation set of 133 serum samples. The marker
Figure 1 Diagnostic performance of single markers for early detection of CRC. Receiver operating characteristics curves regarding the
discrimination between colon cancer and controls for CEA, IL-8 and CRP as single biomarkers with single sample dot plots including specification
of thresholds.
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(95%CI: 36-58%) at a specificity of 86% (95%CI: 73-94%),
while CEA+CRP obtained a sensitivity of 39% (95%CI:
28-50%) at a specificity of 86% (95%CI: 73-94%). Thus,
the diagnostic performance for marker combinations of
CEA, IL-8 and CRP proved to be slightly better in the
validation set. In comparison, the performance of CEA
alone would have reached a sensitivity of only 37% (95%
CI: 29-44%) at the same level of specificity at 86%.
Application of both marker combinations
The marker combinations of CEA+ IL-8 and CEA+CRP
each falsely determined seven of 52 healthy controls to
be malignant. Out of these seven samples, four were
falsely identified by both marker combinations. For
colon carcinomas, the combination CEA+ IL-8 correctly
recognized 39 and CEA+CRP 32 of 81 patients cor-
rectly as malignant. A total of 31 cases overlapped be-
tween both combinations. Combining CEA+ IL-8 withCEA+CRP analysis showed a minimal increased sensi-
tivity of 48% as compared to 47% for CEA+ IL-8 alone,
while specificity decreased from 86% to 80%. Thus, com-
bining both marker combinations did not present a rele-
vant advantage regarding test performance (Additional
file 5: Table S3).
Serum levels and test performance for early stage
carcinomas
When comparing serum levels of CEA and IL-8 between
all early stage (UICC stages I and II, n = 80) and late
stage colon carcinomas (UICC stages III and IV, n = 84),
the median serum level for CEA was 8.00 ng/mL in early
stage and 47.97 ng/mL in late stage carcinomas
(P = 0.0051). The serum levels for IL-8 were 35.78 pg/
mL in early stage and 52.76 pg/mL in late stage carcin-
omas (P = 0.0380). For CRP, median serum level was
3,366 ng/mL in early stage and 4,380 ng/mL in late stage
carcinomas (P > 0.05) (Figure 2). Applying the afore
Table 5 Diagnostic performance of nine serum
biomarkers area under the receiver operating
characteristics curve for all nine analyzed biomarkers in
single analysis for colon cancer cases versus controls



















* Area under the receiver operating characteristics curve.
Figure 2 Detection of early colorectal carcinoma. Dot plots for
serum level of CEA, IL-8 and CRP in control patients in comparison
to early and late colon carcinoma.
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the combined training and validation set, the sensitivity
was 33% (95%CI: 22-44%) for the combination of CEA+
IL-8 and 28% (95%CI: 18-39%) for the combination of
CEA+CRP, each at a specificity of 86% (95%CI: 73-
94%). Looking at the performance of the marker combi-
nations in more detail by each UICC stage separately, at
UICC I (19 cases) the combination of CEA+ IL-8
reached a sensitivity of 21% (95%CI: 8-55%) while CEA+
CRP yielded 5% (95%CI: 0-26%). For UICC II (21 cases),
the sensitivity increased to 48% (95%CI: 26-70%) for
both marker combinations (CEA+ IL-8 and CEA+CRP).
At UICC III (28 cases), the sensitivity was 39% (95%CI:
22-59%) for CEA+ IL-8 and 29% (95%CI: 13-49%) for
CEA+CRP. The highest sensitivity was reached at UICC
IV (15 cases) with 93% (95%CI: 68-100%) for CEA+ IL-8
and 87% (95%CI: 60-98%) for CEA+CRP.Serum levels and test performance for adenomas
We had collected sera from 34 patients in whom the
presence of an adenoma was determined by colonoscopy
(Table 3). The biochip results for all adenomas are
included in Figure 1. The median CEA serum levels of
34 patients with adenomas (0.82 ng/mL) were lower
than the levels observed in all patients with invasive car-
cinomas (1.26 ng/mL). However, the levels weresignificantly higher than the median serum levels of the
healthy controls (0.55 ng/mL, P = 0.0485). For IL-8 the
median serum level for patients with adenomas
(19.97 ng/mL) was also lower than the levels observed in
all patients with invasive carcinoma (27.46 ng/mL) and
in all healthy controls (20.74 ng/mL, both P > 0.05).
Similar results showed CRP with low median levels of
2,020 ng/mL for adenoma patients and higher levels of
4,018 ng/mL for carcinoma patients and 2,086 ng/mL
for healthy controls (both P > 0.05). The afore described
test algorithms were applied to assess the assays
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from healthy controls. First, adenomas were analysed
separately by stage of progression: The sensitivity for the
combination of CEA+ IL-8 was 17% (95%CI: 2-48%) for
non-advanced and 23% (95%CI: 8-45%) for advanced ad-
enomas. For the combination of CEA+CRP, non-
advanced adenomas were detected with a sensitivity of
17% (95%CI: 2-48%) and advanced stage adenomas with
14% (95%CI: 3-35%) (all at a specificity of 86% (95%CI:
73-94%)). The combination of CEA+ IL-8 recognized
two of 12 non-advanced and five of 22 advanced aden-
omas and the combination of CEA+CRP detected also
two of 12 non-advanced and three of 22 advanced aden-
oma patients correctly. For the non-advanced adenomas,
one patient, which was positive detected by CEA+ IL-8
was also detected by CEA+CRP, for the advanced aden-
omas also one positive patient overlapped between both
marker combinations. Second, all adenomas were ana-
lysed as whole group: The sensitivity for the combin-
ation of CEA+ IL-8 was 18% (95%CI: 7-35%) and 15%
(95%CI: 5-31%) for the combination of CEA+CRP, (both
at a specificity of 86% (95%CI: 73-94%)). The combin-
ation of CEA+ IL-8 recognized six and the combination
of CEA+CRP detected five of 34 adenoma patients cor-
rectly. A total of two adenoma patients overlapped be-
tween the two combinations. Application of both
marker combinations simultaneously showed a minim-
ally increased sensitivity of 26%, while the specificity
decreased to 80%.Correlation among biomarker levels and
clinicopathological features
Individuals in the control groups were younger
(62.4 years) than those afflicted with colon cancer
(69.6 years) (P = 0.004). No differences were observed
between adenoma cases and controls regarding the age
of the patients (P = 0.144). Sex was distributed equally
between all groups (P = 0.738). In order to explore
whether the serum levels of the nine tested markers
showed a correlation with age or sex, Spearman´s correl-
ation coefficients were calculated. There was no relevant
correlation between the nine tested markers and age
or sex. However, serum levels of M-CSF correlated
with age within the control-, adenoma- and carcinoma
group (Spearman’s correlation coefficient > 0.35, P < 0.05)
(Additional file 6: Table S4).Discussion
This is the first study to report the development of a
serum biochip array for the simultaneous assessment of
nine serum biomarkers for clinical application to colon
cancer screening in a large and highly standardized
serum sample cohort.Performance of the developed CRCS biochip array
technology
The biochip-array-technology represents a highly stan-
dardized technique for cancer research. Important and
interesting at this point is the simultaneous determin-
ation of multiple analytes in a single patient sample,
whereas ELISAs are limited to single analyte determina-
tions per sample. Therefore, economics of consumables
and most notably sample volume requirements are much
lower for the biochip assay (100 μL total for evaluating
nine analytes simultaneously, equal to 11.1 μL per ana-
lyte), which is an essential advantage concerning precious
clinical samples. In addition, the throughput by a single
operator is much higher for the multiplex assay than for
ELISAs: in our set up 84 patient samples can be pro-
cessed for nine analytes within four hours under highly
standardized conditions. Furthermore, a scale up of the
multiplex assay to even higher throughput is easily pos-
sible by using semi- or full-automation Evidence Multi-
plex Analyzers, which have the capacity to perform a test
output in excess of 1,200 samples for nine analytes simul-
taneously per hour. Several independent studies already
showed the validity of different Randox Evidence Multi-
plex assays [23-26]. For most of the markers it would be
hard to find single ELISAs on the market using exactly
the same antibodies. Thus, in order to test the overall
validity of the multiplex chip assay, CEA, CRP, IL-8 and
VEGF results for the CRCS multiplex array biochip were
compared with commercially established Randox assays
for individual markers using a minimum of 30 human
serum samples. A good correlation was observed for all
four markers tested, with r values > 0.95 (unpublished
data). Therefore, this approach should become of in-
creasing interest when considering limited sample
volumes, costs, high-throughput, and reproducibility.
Diagnostic performance of single markers and marker
combinations
The effectiveness of any screening program depends
not only on economic and operational viability of the
screening test but also on excellent diagnostic perform-
ance. It should be noticed, that the prevalence of colon
cancer and adenomas in our study group is higher than
in the general population. However, our results indicate
that multiplex biochip based serum protein profiling
validated certain biomarkers to discern sera from
patients with and without colon cancer. The analyses
revealed combinations of CEA+ IL-8 and CEA+CRP to
show the best screening performance for colon cancer
reaching a sensitivity of 47% and 39% in the validation
set, respectively. These combinations also proved to be
useful when applied to early carcinoma detection with
33% and 28% sensitivity, respectively, using the com-
bined training and validation set. Applying the test
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sera from patients with colorectal adenomas, we could
show a sensitivity of 18% and 15% sensitivity, respect-
ively (both at 86% specificity). It would be highly desir-
able to directly compare the performance of individual
markers both used here in a multiplex fashion and as
single marker assay reported in the literature. Unfortu-
nately, this comparison can be severely biased, reaching
from different antibodies applied up to different sample
processing and storage conditions. We therefore fo-
cused our analyses primarily on our multiplex results
and those markers with the highest performance either
alone or in combination.
CEA is a well-known serum marker linked to CRC
[27]. It is the most commonly used and studied protein
marker for diagnosis, prognosis, monitoring and recur-
rence after treatment of colorectal carcinomas [28]. CEA
and other CAs tend to be elevated serum marker pro-
teins also for other epithelial malignancies like pancre-
atic carcinomas [29]. Overall sensitivities for detecting
CRC range from 43% to 69% as reviewed by Hundt et al.
[22]. However, we now report for the first time the
evaluation of CEA in combination with IL-8 while we
could show a good diagnostic performance of IL-8 alone
for detecting colon carcinomas previously [13]. In line,
Fernandes et al. found that cytokeratins demonstrate a
greater sensitivity than CEA in the diagnosis of colorec-
tal carcinoma [30]. Lundberg et al. screened 148 patients
regarding the expression of 74 putative biomarkers in
plasma and reported among other markers CEA and IL-
8 to be significantly elevated in CRC compared to
healthy controls. They could hardly detect IL-8 by
ELISA but by a proximity ligation-based multiplex assay
[31]. A combination of CEA and CRP is rarely described:
Stamatiadis et al. analyzed a combination of CEA and
CRP for preoperative staging of colorectal cancer, how-
ever, not for early diagnosis or screening [32]. It has to
be mentioned though that not a multiplex array but a
retrospective statistical combination of separate assess-
ments of both markers was used.
Currently established screening test
Mortality from CRC can be reduced by early detection
of cancer and removal of adenomas [33,34]. Based on
this evidence, a number of countries have already intro-
duced screening programs for CRC. Besides colonos-
copy, the most common, non-invasive screening tool for
colorectal cancer is fecal occult blood testing (FOBT).
Several studies have shown that annual or biennial
screening in asymptomatic people over the age of
50 years using FOBTs can reduce CRC mortality by 15–
33% [35-37]. Diagnostic performance of FOBTs has
greatly improved throughout the last 50 years. In 1986,
Bang et al. reported a sensitivity of 25% at 98%specificity for detecting CRC [38]. In 1997, Ransohoff
et al. reported 30 to 50% sensitivity at 84 to 96% specifi-
city for FOBTs [39]. iFOBT displayed higher sensitivity
of 61–91% for CRC and showed a clinically superior ac-
curacy [40] at specificity varying from 91% to 98% [41].
Adenoma detection
Besides carcinomas, detection of early neoplasm like ad-
enomas is favourable. For iFOBTs, sensitivities for
detecting adenomas range from 4% to 63% for all aden-
omas, and 28% to 67% for adenomas of 1 cm or larger,
both at a specificity of 89% [42]. Among the 34 adenoma
patients included in our study were 12 early stage and
22 advanced adenomas [43]. The multiplex biochip
showed a sensitivity of 18% for CEA+ IL-8 and 15% for
CEA+CRP, both at 86% specificity. While the detection
of adenomas by serum protein markers might still be
unexpected due to the relatively small lesion size and
pre-malignant characteristics as compared to invasive
carcinomas, our results fall into sensitivity ranges
reported for various other approaches. In addition, the
sensitivity of our biochip array can likely be improved by
the addition of further promising markers.
Compliance of current screening methods
The effectiveness of any screening program depends
not only on the diagnostic and economic performance
of the screening test but also to a large extent on the
compliance and general acceptance of the test by the
public. Indeed, the compliance for colonoscopy is quite
low compared to FOBTs [44]. Colonoscopy is thought
to be time consuming, disturbing, painful and involv-
ing risk [45]. In contrast, 88.8% of patients reported
that they would perform the fecal occult blood test
(FOBT) for CRC screening if so requested by doctors
[45]. If the FOBT was positive and a colonoscopy was
offered, 84.9% of participants indicated that they would
undergo the procedure [45]. Against this background it
can easily be envisioned that a blood test would even
reach comparable if not even a higher compliance
compared to FOBT testing. While new screening tech-
nologies might enable detecting changes in bloods’
cfDNA and miRNA composition, proteins are more
likely to present the actual disease phenotype. How-
ever, it would be desirable for future studies to com-
pare the most potent screening assays including
known markers, e.g. CEA and CA19-9.
Conclusions
Our novel multiplex biochip revealed combinations of
CEA+ IL-8 and CEA+CRP to show the best screening
performance for colon cancer with 47% sensitivity, for
early carcinomas with 33% sensitivity, and adenomas
with 18% sensitivity at an overall specificity of 86%. This
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ther promising markers. Since neither compliance nor
diagnostic performance of FOBTs and serum markers
alone seems satisfying for early colon cancer detection
today, a combination of both methods may improve the
performance of colon cancer screening.
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